Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized trial of TIL therapy plus interleukin-2 versus ipilimumab in metastatic melanoma
2013-005406-54Phase 3Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2014
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of autologous tumor-infiltrating lymphocytes, aldesleukin, ipilimumab, cyclophosphamide and fludarabine in melanoma (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoint: Progression-free survival at 6 months. Started Mar 2014; status: completed.
02
Drugs
autologous tumor-infiltrating lymphocytesaldesleukinipilimumabcyclophosphamidefludarabine
03
Conditions
melanoma
Beyond the preview
Go deeper on 2013-005406-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005406-54.